Cargando…

Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients

Detalles Bibliográficos
Autores principales:	Al-Busafi, Said A., Omar, Heba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539682/ https://www.ncbi.nlm.nih.gov/pubmed/28721982 http://dx.doi.org/10.4103/sjg.SJG_136_17

Ejemplares similares

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
por: Hill, Andrew, et al.
Publicado: (2014)

Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals
por: Yoo, Eric R., et al.
Publicado: (2017)

The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada
por: Chu, Cherry, et al.
Publicado: (2023)

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India
por: Aggarwal, Rakesh, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany
por: Runge, Melanie, et al.
Publicado: (2020)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
por: Wong, Yu Jun, et al.
Publicado: (2021)

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong
por: Yuen, Man-Fung, et al.
Publicado: (2020)

Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries
por: Jung, Jeah, et al.
Publicado: (2020)

Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan
por: Zhuo, Yueran, et al.
Publicado: (2020)

The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders
por: Jiang, Xinyi, et al.
Publicado: (2021)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States
por: Park, Haesuk, et al.
Publicado: (2019)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
por: Barber, Melissa J., et al.
Publicado: (2020)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy
por: Girardin, François, et al.
Publicado: (2021)

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries
por: Mennini, Francesco S., et al.
Publicado: (2021)

Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid
por: Pham, Timothy T., et al.
Publicado: (2018)

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
por: Simoes, Camila C., et al.
Publicado: (2019)

Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages
por: Suenaga, Riichiro, et al.
Publicado: (2021)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_og3i18un9u1ecjtpoqt2oqglgl